Navigation Links
Albert Einstein Cancer Center begins 40th year of continuous NIH support with $17 million grant
Date:9/26/2013

September 26, 2013 (BRONX, NY) For the past four decades, scientists and clinicians at Albert Einstein Cancer Center (AECC) have made major contributions to research on many aspects of the cancer problem. With the recent renewal of the center's $16.7 million grant from the National Cancer Institute (NCI), AECC members will continue to investigate the underlying causes of cancer and new approaches to the prevention, diagnosis and treatment of these diseases.

"Our faculty is pleased and proud to have competed so favorably in the peer-review process that resulted in the renewal of this grant, particularly at a time of diminishing NCI support for cancer research," said I. David Goldman, M.D., director of AECC at Albert Einstein College of Medicine of Yeshiva University. Dr. Goldman is also professor of medicine and of molecular pharmacology and holds the Susan Resnick Fisher Chair at Einstein.

AECC was one of the first academic cancer research centers to receive an NCI designation, which it has held since 1972. Currently, there are 68 such centers throughout the United States. Since AECC's creation, its researchers have made notable fundamental scientific discoveries that have elucidated why cancers form, grow and spread. AECC's clinical scientists are developing novel approaches to cancer treatment and the center's epidemiologists are making major contributions to the understanding of the viral and other environmental causes of cancer and its prevention. AECC is a national resource for these studies given the diverse ethnic and racial populations in the Bronx.

This grant will provide continued support for five ongoing interdisciplinary research programs that form the basis of AECC's laboratory and translational work: tumor microenvironment and metastasis; stem cells, differentiation and cancer; experimental therapeutics; cancer epidemiology; and the biology of colon cancer. These research programs are supported by 14 specialized shared resource facilities that range from genomics and proteomics to biostatistics and bioinformatics. AECC also provides comprehensive support for, and oversight of, its clinical cancer research activities conducted at the Montefiore-Einstein Center for Cancer Care.


'/>"/>

Contact: Deirdre Branley
sciencenews@einstein.yu.edu
347-266-9204
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. UAlberta prostate cancer researcher and team developing homing beacon drugs to target cancer cells
2. UAlberta medical researchers make key discovery in fight against Alzheimers disease
3. UAlberta medical researchers discover new potential chemotherapy
4. Alternative medicine use high amoung children with chronic conditions: UAlberta medical research
5. Alternative medicine use high among children with chronic conditions: UAlberta medical research
6. New UAlberta research shows commonly prescribed medications could have adverse effects
7. UAlberta researcher pinpoints prescription for successful Primary Care Networks
8. Albertson & Davidson, LLP Obtains Court Order Requiring California Trustee to Provide Pre-Death Accounting
9. Dr. Anne Gershon receives 2013 Albert B. Sabin Gold Medal Award
10. Stadler Form’s Revolutionary Dehumidifier, Albert, Makes Its Debut at Humidifiers.com
11. DiscountFurnaceFilter.com Introduces the Latest Innovative Creation from Stadler Form, Albert the Dehumidifier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... Freedom, PA (PRWEB) , ... April 22, 2017 ... ... healthcare experience to his role as Vice President of Sales and Business Development ... of key GPO/IDN business partner engagements, business development, and strategic planning for the ...
(Date:4/21/2017)... ... April 21, 2017 , ... The staff at Palm Beach Face is proud to announce ... the 2017 London Marathon. Set to take place on April 23rd, the London Marathon has ... Schwartz will run as part of team EMPOWER, raising money for the international charity, Smile ...
(Date:4/21/2017)... Wis. (PRWEB) , ... April 21, 2017 , ... ... today announced that its B-595 and B-7569 vinyl label materials ... identification and warning labels are tested to remain intact and legible, for use on ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community of ... with the 2017 Ruth Ravich Patient Advocacy Award in recognition of her ... was honored with the award at The Beryl Institute’s annual Patient Experience Conference ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... weeklong campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 ... treating and preventing substance use disorders. , The mission of AWARE is ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence that ... Parkinson,s, according to a study released today that will be ... Meeting in Boston , April 22 ... the treatment of Parkinson,s disease, the oral drug levodopa has ... and longevity. But as the disease progresses, the effects of ...
(Date:4/19/2017)... OAKS, Calif. , April 19, 2017 /PRNewswire/ ... industrial buildings it is developing at Conejo Spectrum ... , to Atara Biotherapeutics, Inc. , ... with severe and life-threatening diseases that have been ... on allogeneic T-cell therapies for cancer, autoimmune and ...
Breaking Medicine Technology: